Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective.

abstract：BACKGROUND:In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this hypothesis, we analyzed TP53 mutations and downregulation of p14(arf), a negative regulator of p53 activated by on...

journal_title：Clinical lung cancer

authors： Cortot AB,Younes M,Martel-Planche G,Guibert B,Isaac S,Souquet PJ,Commo F,Girard P,Fouret P,Brambilla E,Hainaut P,Soria JC

更新日期：2014-03-01 00:00:00

abstract：INTRODUCTION:Small-cell lung cancer (SCLC) is a highly vascularized tumor. ASA404 is a tumor vascular disrupting agent. This is the first trial to report the effects of combining chemotherapy with ASA404 in SCLC. METHODS:Patients with untreated metastatic SCLC were treated with carboplatin (area under curve, 6) plus p...

journal_title：Clinical lung cancer

authors： Früh M,Cathomas R,Siano M,Tscherry G,Zippelius A,Mamot C,Erdmann A,Krasniqi F,Rauch D,Simcock M,Küttel E,Fustier P,Pless M,Swiss Group for Clinical Cancer Research.

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Elderly patients are underrepresented in trials that establish definitive chemoradiotherapy as the standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC). This study analyzed radiotherapy treatment delivery and outcomes at our institution according to elderly (≥ 70 years old) or youn...

journal_title：Clinical lung cancer

authors： Aridgides PD,Janik A,Bogart JA,Duffy S,Rosenbaum P,Gajra A

更新日期：2013-11-01 00:00:00

abstract：INTRODUCTION:We examined mutational testing of the epidermal growth factor gene (EGFR) and erlotinib treatment among veterans diagnosed with non-small-cell lung cancer in the United States Department of Veterans Affairs (VA). Our objectives were to identify the prevalence of clinically actionable EGFR mutations, to det...

journal_title：Clinical lung cancer

authors： Lynch JA,Berse B,Chun D,Rivera D,Filipski KK,Kulich S,Viernes B,DuVall SL,Kelley MJ

更新日期：2017-07-01 00:00:00

abstract：UNLABELLED:Extrapolation of clinical trials results to the general population is always challenging. We analysed 1047 patients diagnosed with an advanced stage disease between 1998 and 2005 in a french administrative department and found a good spread of modern chemotherapy since 1998 and targeted therapy since 2002. M...

journal_title：Clinical lung cancer

authors： Carpentier O,Selvaggi L,Jégu J,Purohit A,Prim N,Velten M,Quoix E

更新日期：2015-11-01 00:00:00

abstract：PURPOSE:Lung cancer is an epidemic disease in developing countries. Incorporation of new active drugs in the neoadjuvant treatment of operable patients might lead to improved outcomes. Postchemotherapy mediastinal-based treatment decisions allow for in vivo testing of activity and could help to determine the ideal loca...

journal_title：Clinical lung cancer

authors： Martins RG,Dienstmann R,de Biasi P,Dantas K,Santos V,Toscano E,Roriz W,Zamboni M,Sousa A,Small IA,Moreira D,Ferreira CG,Zukin M

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-...

journal_title：Clinical lung cancer

authors： Lin C,Chen X,Li M,Liu J,Qi X,Yang W,Zhang H,Cai Z,Dai Y,Ouyang X

更新日期：2015-09-01 00:00:00

abstract：:An early phase II study of topotecan produced favorable results in a small number of untreated and previously treated patients with small-cell lung cancer (SCLC). This multicenter study was conducted in patients with relapsed SCLC at 19 medical institutions in Japan. Topotecan 1.0 mg/m2/day was administered for 5 cons...

journal_title：Clinical lung cancer

authors： Takeda K,Negoro S,Sawa T,Nakagawa K,Kawahara M,Isobe T,Kudoh S,Masuda N,Niitani H,Fukuoka M

更新日期：2003-01-01 00:00:00

abstract：INTRODUCTION:We set out to investigate whether volumetric tumor measurements allow for a prediction of treatment response, as measured by patient survival, in patients with advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS:Patients with nonresectable NSCLC (stage III or IV, n = 100) who were repeatedl...

journal_title：Clinical lung cancer

authors： Knollmann FD,Kumthekar R,Fetzer D,Socinski MA

更新日期：2014-03-01 00:00:00

abstract：:Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...

journal_title：Clinical lung cancer

authors： Socinski MA

更新日期：2010-05-01 00:00:00

abstract：:Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The associ...

journal_title：Clinical lung cancer

authors： Imbimbo M,Vitali M,Fabbri A,Ottaviano M,Pasello G,Petrini I,Palmieri G,Berardi R,Zucali P,Ganzinelli M,Marabese M,Broggini M,Marino M,Trama A,Rulli E,Hollander L,Pruneri G,Torri V,Garassino MC

更新日期：2018-09-01 00:00:00

abstract：INTRODUCTION:For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. PATIENTS AND METHODS:From February 2017 through Februa...

journal_title：Clinical lung cancer

authors： Gerber DE,Hamann HA,Chavez C,Dorsey O,Santini NO,Browning T,Ochoa CD,Adesina J,Natchimuthu VS,Steen E,Zhu H,Lee SJC

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) in high-risk patients, but a minority of eligible people are screened. It is not clear whether knowledge of USPSTF recommendations among primary care physicians (PCP) affe...

journal_title：Clinical lung cancer

authors： Raz DJ,Wu GX,Consunji M,Nelson RA,Kim H,Sun CL,Sun V,Kim JY

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:In the present study we aimed to investigate whether the predominance of the lepidic component in tumors was associated with the outcome of postoperative adjuvant chemotherapy for stage I lung adenocarcinoma. PATIENTS AND METHODS:Charts for patients with pathological stage I lung adenocarcinoma were retrosp...

journal_title：Clinical lung cancer

authors： Sasada S,Miyata Y,Mimae T,Tsutani Y,Mimura T,Okada M

更新日期：2016-09-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

journal_title：Clinical lung cancer

authors： Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

更新日期：2004-03-01 00:00:00

abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

journal_title：Clinical lung cancer

authors： Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

更新日期：2001-08-01 00:00:00

abstract：BACKGROUND:Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS:From 2008 to 2011, 130 ...

journal_title：Clinical lung cancer

authors： Zenke Y,Yoh K,Matsumoto S,Umemura S,Niho S,Ohmatsu H,Goto K,Ohe Y

更新日期：2016-09-01 00:00:00

abstract：:Lobectomy remains the standard procedure for early-stage non small-cell lung cancer (NSCLC). Advances in minimally invasive surgery allow lobectomy to be performed by videothoracoscopy (VATSLOBE). The objective of this study was to compare open thoracotomy (OPENLOBE) to VATSLOBE in the treatment of early-stage NSCLC. ...

journal_title：Clinical lung cancer

authors： Luketich JD,Meehan MA,Landreneau RJ,Christie NA,Close JM,Ferson PF,Keenan RJ,Belani CP

更新日期：2000-08-01 00:00:00

abstract：BACKGROUND:There are few reports of treatment and outcome for patients with metachronous or synchronous lung and gastric cancers. To evaluate them, we conducted a retrospective study. PATIENTS AND METHODS:The medical records of patients with lung cancer who previously or simultaneously had gastric cancer seen in our d...

journal_title：Clinical lung cancer

authors： Kurishima K,Satoh H,Kagohashi K,Homma S,Nakayama H,Ohara G,Ishikawa H,Hizawa N

更新日期：2009-11-01 00:00:00

abstract：:Both gemcitabine and carboplatin have demonstrated activity in advanced non small-cell lung cancer. The combination of gemcitabine and cisplatin has demonstrated equivalent or superior efficacy to other commonly used agents and two-drug combinations, and a recent Eastern Cooperative Oncology Group trial suggested that...

journal_title：Clinical lung cancer

authors： Masters GA

更新日期：2000-12-01 00:00:00

abstract：:Multiple studies have confirmed the value of radiation therapy in limited-stage small-cell lung cancer. The appropriate dose of radiation and the optimal fractionation scheme, however, remain controversial. This article will examine the history of radiation therapy in the management of small-cell lung cancer. It will ...

journal_title：Clinical lung cancer

authors： Roof KS,Fidias P,Lynch TJ,Choi NC

更新日期：2003-05-01 00:00:00

abstract：INTRODUCTION:Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. PATIENTS AND METHODS:The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and compl...

journal_title：Clinical lung cancer

authors： Eze C,Roengvoraphoj O,Niyazi M,Hildebrandt G,Fietkau R,Belka C,Manapov F

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:Human immunodeficiency virus (HIV)-infected individuals are at increased risk for primary lung cancer (LC). We wished to compare the clinicopathologic features and treatment outcome of HIV-LC patients with HIV-indeterminate LC patients. We also sought to compare behavioral characteristics and immunologic fea...

journal_title：Clinical lung cancer

authors： D'Jaen GA,Pantanowitz L,Bower M,Buskin S,Neil N,Greco EM,Cooley TP,Henry D,Stem J,Dezube BJ,Stebbing J,Aboulafia DM

更新日期：2010-11-01 00:00:00

abstract：BACKGROUND:Pulmonary function tests are used to select patients with non-small-cell lung cancer (NSCLC) suitable for thoracic surgery. We studied the impact of pulmonary function tests on both quantitative (morbidity, mortality, and overall survival [OS]) and qualitative (quality of life [QOL]) outcomes of patients und...

journal_title：Clinical lung cancer

authors： Greillier L,Thomas P,Loundou A,Doddoli C,Badier M,Auquier P,Barlési F

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kir...

journal_title：Clinical lung cancer

authors： Schuette W,Behringer D,Stoehlmacher J,Kollmeier J,Schmager S,Fischer von Weikersthal L,Schumann C,Buchmann J

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Cancer-associated macrophage-like cells (CAMLs) are a potential peripheral blood biomarker for disease progression. This study used data from a phase 2 clinical trial to evaluate prognostic utility of CAMLs for locally advanced non-small-cell lung cancer treated with definitive chemoradiotherapy (CRT) and at...

journal_title：Clinical lung cancer

authors： Augustyn A,Adams DL,He J,Qiao Y,Verma V,Liao Z,Tang CM,Heymach JV,Tsao AS,Lin SH

更新日期：2020-06-20 00:00:00

abstract：BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

journal_title：Clinical lung cancer

authors： Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS:To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the ...

journal_title：Clinical lung cancer

authors： Nakamichi S,Horinouchi H,Asao T,Goto Y,Kanda S,Fujiwara Y,Nokihara H,Yamamoto N,Ito Y,Watanabe SI,Ohe Y

更新日期：2017-11-01 00:00:00

abstract：INTRODUCTION:Computed tomography (CT)-guided lung biopsy is occasionally used for the lesions that were diagnosed as nonmalignant by transbronchial examination despite the fact that other clinical data suggested those as malignant. The purpose of this study is to evaluate the outcomes of CT fluoroscopy-guided cutting n...

journal_title：Clinical lung cancer

authors： Matsui Y,Hiraki T,Mimura H,Gobara H,Inoue D,Iishi T,Toyooka S,Kanazawa S

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Central nervous system (CNS) progression is a common manifestation of acquired resistance to crizotinib in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). However, an optimal tailored treatment approach has not been established in patients with CNS failure during crizotinib tr...

journal_title：Clinical lung cancer

authors： Zhao Y,Zhang B,Wang S,Qiao R,Xu J,Zhang L,Zhang Y,Han B

更新日期：2019-11-01 00:00:00